The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.

In this single-centre study of 881 patients, S-phase fraction (SPF) was shown to be a significant prognostic marker in terms of overall survival (OS), relapse-free survival (RFS) and survival after relapse (SAR). Further, SPF had independent prognostic significance when considering a range of other clinicopathological variables, namely tumour grade and stage, nodal status, patient age, tumour size, menstrual status and treatment details. For OS and RFS, SPF was the second strongest predictor of the clinical course of the disease after nodal status, and for SAR it was the strongest prognostic marker. SPF correlated positively with histological grade but was the stronger predictor of survival. The distribution of SPF values was markedly different for the two ploidy classes of tumour, with DNA aneuploid tumours having a significantly higher average SPF. However, SPF retained its independent prognostic ability when DNA diploid and aneuploid tumours were analysed separately, DNA ploidy itself also proved to be an independent prognostic marker but the survival difference between the two ploidy classes was much less than that seen for different levels of SPF. Tumours with several DNA aneuploid populations (multiploid tumours) tended to have a worse prognosis than other aneuploid tumours but this trend did not reach statistical significance. In this and other studies from this centre, SPF has proved to be a robust predictor of clinical outcome in carcinoma of the breast.

[1]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[2]  R. K. Knight,et al.  CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER , 1983, The Lancet.

[3]  R. Camplejohn,et al.  Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. , 1987, British Journal of Cancer.

[4]  M. Palmer,et al.  The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. , 1988, British Journal of Cancer.

[5]  H. Joensuu,et al.  The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. , 1989, British Journal of Cancer.

[6]  R. Camplejohn,et al.  Measurement of S-phase fractions in lymphoid tissue comparing fresh versus paraffin-embedded tissue and 4',6'-diamidino-2 phenylindole dihydrochloride versus propidium iodide staining. , 1989, Cytometry.

[7]  L L Vindeløv,et al.  A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.

[8]  W. McGuire,et al.  Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors , 1990, Cancer.

[9]  M. Fernö,et al.  Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.

[10]  J Grogono,et al.  Node negative breast cancer. , 1990, BMJ.

[11]  R. Camplejohn,et al.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Souhami,et al.  A mathematical model relating response durations to amount of subclinical resistant disease. , 1991, Cancer research.

[13]  J. Winstanley,et al.  Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. , 1992, British Journal of Cancer.

[14]  V. Kosma,et al.  DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer , 1992, International journal of cancer.

[15]  R. Camplejohn A role for proliferative measurements in clinical oncology? , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Underwood Diagnostic Molecular Pathology. A Practical Approach , 1993 .

[17]  G. Del Bino,et al.  Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  London Scottish Cancer Trials Breast Group And Icrf Breas GUY'S HOSPITAL Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial , 1993, The Lancet.

[19]  A. Howell,et al.  A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. , 1994, British Journal of Cancer.

[20]  D.,et al.  Regression Models and Life-Tables , 2022 .